Seaport Therapeutics, Inc. (SPTX) stock
SPTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026
$18.31+0.14 (+0.77%)
Close on Nov 18, 2026Market cap $980.14MP/E –Yield –
Seaport Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$30.35M | – |
| Q2 FY2026 | Jun 30, 2026 | -$65.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.47M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.19M | – |
See a number that looks wrong?